Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk ALIMENTARY PHARMACOLOGY & THERAPEUTICS Hsu, Y., Nguyen, M. H., Mo, L., Wu, M., Yang, T., Chen, C., Tseng, C., Tai, C., Wu, C., Lin, J., Tanaka, Y., Chang, C. 2019; 49 (1): 107–15

View details for DOI 10.1111/apt.15058

View details for Web of Science ID 000452872100013